Heparin localization and fine structure regulate Burkitt's lymphoma growth

Biochemical and Biophysical Research Communications

Volumn 348, Issue 3, 2006, Pages 850-856

  Berry, David ^a,b,c   Lynn, David M ^d   Berry, Eric ^b,c   Sasisekharan, Ram ^b,c,e   Langer, Robert ^b,c,f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Biological Engineering Division   (United States)

^d University of Wisconsin Madison   (United States)

^e Center for Biomedical Engineering   (United States)

^f Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Cancer; Epstein Barr virus; Fibroblast growth factor; Heparan sulfate; Heparinase; Poly( amino ester)

Indexed keywords

ESTER DERIVATIVE; HEPARIN; HEPARIN LYASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; POLY BETA AMINO ESTER; PROTEOHEPARAN SULFATE; UNCLASSIFIED DRUG;

ARTICLE; BURKITT LYMPHOMA; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INHIBITION; DRUG POTENCY; ENZYME REGULATION; EPSTEIN BARR VIRUS; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN FUNCTION;

BURKITT LYMPHOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GROWTH INHIBITORS; HEPARIN; HUMANS; UP-REGULATION;

HUMAN HERPESVIRUS 4;

EID: 33747162238     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.07.128     Document Type: Article

References (40)

1. Klein G. Specific chromosomal translocations and the genesis of B-cell-derived tumors in mice and men. Cell 32 (1983) 311-315
2. Klein G. The role of gene dosage and genetic transpositions in carcinogenesis. Nature 294 (1981) 313-318
3. Gavioli R., Frisan T., Vertuani S., Bornkamm G.W., and Masucci M.G. c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells. Nat. Cell Biol. 3 (2001) 283-288
4. Ruf I.K., Rhyne P.W., Yang H., Borza C.M., Hutt-Fletcher L.M., Cleveland J.L., and Sample J.T. Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol. Cell. Biol. 19 (1999) 1651-1660
5. Ruf I.K., Rhyne P.W., Yang H., Borza C.M., Hutt-Fletcher L.M., Cleveland J.L., and Sample J.T. EBV regulates c-MYC, apoptosis, and tumorigenicity in Burkitt's lymphoma. Curr. Top. Microbiol. Immunol. 258 (2001) 153-160
6. Perrimon N., and Bernfield M. Specificities of heparan sulphate proteoglycans in developmental processes. Nature 404 (2000) 725-728
7. Esko J.D., and Lindahl U. Molecular diversity of heparan sulfate. J. Clin. Invest. 108 (2001) 169-173
8. Blackhall F.H., Merry C.L., Davies E.J., and Jayson G.C. Heparan sulfate proteoglycans and cancer. Br. J. Cancer 85 (2001) 1094-1098
9. Iozzo R.V., and San Antonio J.D. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J. Clin. Invest. 108 (2001) 349-355
10. Wakisaka N., Murono S., Yoshizaki T., Furukawa M., and Pagano J.S. Epstein-barr virus latent membrane protein 1 induces and causes release of fibroblast growth factor-2. Cancer Res. 62 (2002) 6337-6344
11. Ornitz D.M. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 22 (2000) 108-112
12. Rapraeger A.C., Kruffka A., and Olwin B.B. Requirement of heparin sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 252 (1991) 1705-1708
13. Spivak-Kroizman T., Lemmon M.A., Dikic I., Ladbury J.E., Pinchasi D., Huang J., Jaye M., Crumley G., Schlessinger J., and Lax I. Heparin-induced oligomerization of FGF molecules is responsible fo FGF receptor dimerization, activation, and cell proliferation. Cell 79 (1994) 1015-1024
14. Ho C.L., Sheu L.F., and Li C.Y. Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma. Appl. Immunohistochem. Mol. Morphol. 10 (2002) 316-321
15. Padera R., Venkataraman G., Berry D., Godvarti R., and Sasisekharan R. FGF-2/fibroblast growth factor receptor/heparin-like glycosaminoglycan interactions: a compensation model for FGF-2 signaling. FASEB J. 13 (1999) 1677-1687
16. Sebestyen A., Totth A., Mihalik R., Szakacs O., Paku S., and Kopper L. Syndecan-1-dependent homotypic cell adhesion in HT58 lymphoma cells. Tumour Biol. 21 (2000) 349-357
17. Fitzgerald M.L., Wang Z., Park P.W., Murphy G., and Bernfield M. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J. Cell. Biol. 148 (2000) 811-824
18. Inman G.J., Binne U.K., Parker G.A., Farrell P.J., and Allday M.J. Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death. J. Virol. 75 (2001) 2400-2410
19. Klein E., Klein G., Nadkarni J.S., Nadkarni J.J., Wigzell H., and Clifford P. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res. 28 (1968) 1300-1310
20. Nanbo A., Inoue K., Adachi-Takasawa K., and Takada K. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma. EMBO J. 21 (2002) 954-965
21. Berry D., Lynn D.M., Sasisekharan R., and Langer R. Poly(beta-amino ester)s promote cellular uptake of heparin and cancer cell death. Chem. Biol. 11 (2004) 487-498
22. Lynn D.M., Anderson D.G., Putnam D., and Langer R. Accelerated discovery of synthetic transfection vectors: parallel synthesis and screening of a degradable polymer library. J. Am. Chem. Soc. 123 (2001) 8155-8156
23. Folkman J., Langer R., Linhardt R.J., Haudenschild C., and Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 221 (1983) 719-725
24. Sasisekharan R., Shriver Z., Venkataraman G., and Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat. Rev. Cancer 2 (2002) 521-528
25. Ernst S., Langer R., Cooney C.L., and Sasisekharan R. Enzymatic degradation of glycosaminoglycans. Crit. Rev. Biochem. Mol. Biol. 30 (1995) 387-444
26. Ricard-Blum S., Beraud M., Raynal N., Farndale R.W., and Ruggiero F. Structural requirements for heparin/heparan sulfate binding to type V collagen. J. Biol. Chem. (2006)
27. Chu C.L., Goerges A.L., and Nugent M.A. Identification of common and specific growth factor binding sites in heparan sulfate proteoglycans. Biochemistry 44 (2005) 12203-12213
28. Liu D., Shriver Z., Venkataraman G., El Shabrawi Y., and Sasisekharan R. Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc. Natl. Acad. Sci. USA 99 (2002) 568-573
29. Fannon M., Forsten K.E., and Nugent M.A. Potentiation and inhibition of bFGF binding to heparin: a model for regulation of cellular response. Biochemistry 39 (2000) 1434-1445
30. Lynn D.M., and Langer R. Degradable poly(β-amino esters): synthesis, characterization, and self-assembly with plasmid DNA. J. Am. Chem. Soc 122 (2000) 10761-10768
31. Ong S.H., Guy G.R., Hadari Y.R., Laks S., Gotoh N., Schlessinger J., and Lax I. FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors. Mol. Cell. Biol. 20 (2000) 979-989
32. Ong S.H., Hadari Y.R., Gotoh N., Guy G.R., Schlessinger J., and Lax I. Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc. Natl. Acad. Sci. USA 98 (2001) 6074-6079
33. Fannon M., and Nugent M.A. Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate. J. Biol. Chem. 271 (1996) 17949-17956
34. Alexander C.M., Reichsman F., Hinkes M.T., Lincecum J., Becker K.A., Cumberledge S., and Bernfield M. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat. Genet. 25 (2000) 329-332
35. Yun M.S., Kim S.E., Jeon S.H., Lee J.S., and Choi K.Y. Both ERK and Wnt/{β}-catenin pathways are involved in Wnt3a-induced proliferation. J. Cell. Sci. (2004)
36. Morrison J.A., Gulley M.L., Pathmanathan R., and Raab-Traub N. Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res. 64 (2004) 5251-5260
37. Scholle F., Bendt K.M., and Raab-Traub N. Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J. Virol. 74 (2000) 10681-10689
38. Morrison J.A., Klingelhutz A.J., and Raab-Traub N. Epstein-Barr virus latent membrane protein 2A activates beta-catenin signaling in epithelial cells. J. Virol. 77 (2003) 12276-12284
39. Cobel-Geard R.J., and Hassouna H.I. Interaction of protamine sulfate with thrombin. Am. J. Hematol. 14 (1983) 227-233
40. Teoh K.H., Young E., Bradley C.A., and Hirsh J. Heparin binding proteins. Contribution to heparin rebound after cardiopulmonary bypass. Circulation 88 (1993) II420-II425